Carboplatin delays mammary cancer 4T1 growth in mice

Pathology Research and Practice

Volumn 209, Issue 1, 2013, Pages 24-29

  Souza, Cristina Maria de ^a   Gamba, Conrado de Oliveira ^a   Campos, Cecília Bonolo de ^a   Lopes, Miriam Teresa Paz ^a   Ferreira, Mônica Alves Neves Diniz ^a   Andrade, Silvia Passos ^a   Cassali, Geovanni Dantas ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Carboplatin; Cell proliferation; Immunohistochemical; Mammary cancer model

Indexed keywords

CARBOPLATIN; CYCLIN D1; ONCOPROTEIN; PROTEIN CDC47; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MITOSIS INDEX; MOUSE; NONHUMAN; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84872389062     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.10.003     Document Type: Article

References (36)

1. Bachmann J., Friess H., Martignoni M.E. Molecular mechanisms and its clinical impact in cancer cachexia. Z. Gastroenterol. 2008, 46:1384-1392.
2. Bartek J., Lukas J., Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of conditional haploinsufficiency. Cell Cycle 2007, 6:2344-2347.
3. Belani C.P. Recent updates in the clinical use of platinum compounds for the treatment of lung, breast, and genitourinary tumors and myeloma. Semin. Oncol. 2004, 31(Suppl. 14):25-33.
4. Birnabaum A., Dipetrillo T., Rathore R., et al. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Am. J. Clin. Oncol. 2010, 33:144-147.
5. Dalton S., Whitbread L. Cell cycle-regulated nuclear import and export of Cdc47, a protein essential for initiation of DNA replication in budding yeast. Proc. Natl. Acad. Sci U.S.A. 1995, 92:2514-2518.
6. Dutra A.P., Azevedo-Júnior G.M., Schmitt F.C., et al. Assessment of cell proliferation and prognostic factors in canine mammary gland tumors. Arq. Bras. Med. Vet. Zootec. 2008, 60:1403-1412.
7. Ferreira E., Gobbi H., Saraiva B.S., et al. Columnar cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis. BMC Cancer 2010, 23:61.
8. Ferreira L.M., Hochman B., Barbosa M.V.J. Experimental models in research. Acta Cirúrg. Bras. 2005, 20:28-34.
9. Fornier M.N. Approved agents for metastatic breast cancer. Semin. Oncol. 2011, 38(Suppl. 2):S3-S10.
10. Fulzele S.V., Chatterjee A., Shaik M.S., et al. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm. Res. 2006, 9:2094-2106.
11. Gao J., Liu Y.G., Zingaro R.A. Cytotoxic activities, cellular uptake, gene regulation, and optical imaging of novel platinum(II) complexes. Chem. Res. Toxicol. 2009, 22:1705-1712.
12. Greenberg S., Stopeck A., Rugo H.S. Systemic treatment of early breast cancer a biological perspective. J. Surg. Oncol. 2011, 103:619-626.
13. Gueta I., Altman A., Shoenfeld Y. The effect of blocking TNF-alpha in patients with cancer-related cachexia and anorexia. Harefuah 2010, 149:512-514.
14. Homesley L., Lei M., Kawasaki Y., et al. Mcm10 and the MCM2-7 complex interact to initiate DNA synthesis and to release replication factors from origins. Genes Dev. 2000, 14:913-926.
15. Israyelyan A., Shannon E.J., Baghian A., et al. Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother. Pharmacol. 2009, 6:1201-1210.
16. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Ver. Cancer 2007, 7:573-584.
17. Langer C., Millenson M., Rosvold E., et al. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network. Semin. Oncol. 1997, 24:S12-S81.
18. Ledermann J.A. Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis?. Int. J. Gynecol. Cancer 2011, 10(Suppl. 1):S9-S11.
19. Maeda K., Chung Y.S., Takatsuka S., et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br. J. Cancer 1995, 72:319-323.
20. Martín M. Platinum compounds in the treatment of advanced breast cancer. Clin. Breast Cancer 2001, 2:190-208.
21. Miller K.D., Sweeney C.J., Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 2001, 19:1195-1206.
22. Nguyen V.Q., CO C., Li J.J. Cyclin-dependent kinases prevent DNA re-replication through multiple mechanisms. Nature 2001, 411:28.
23. Ott I., Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anti-Cancer Agents Med. Chem. 2007, 7:95-110.
24. Pulaski B.A., Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 1998, 7:1486-1493.
25. Quintana E., Pertusa J., González R., Renau-Piqueras Carboplatin treatment induces dose-dependent increases in the frequency of micronuclei in Ehrlich ascites tumor cells. J. Mutat. Res. 1994, 1:55-60.
26. Rabik C., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33:9-23.
27. Reles A., Wen H., Wen A.S., et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 2001, 7:2984-2997.
28. Rosenberg B., Vancamp L., Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965, 13:698-709.
29. Sanborn R.E. Cisplatin versus carboplatin in NSCLC: is there one "best" answer?. Curr. Treat. Options Oncol. 2008, 4:326-342.
30. Sauter E.R., Nesbit M., Litwin S., Klein-Szanto A.J., Cheffetz S., Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinoma. Cancer Res. 1999, 59:4876-4881.
31. Shimizu T., Yoshida M., Makishima K. Importance of AUC of carboplatin in head and neck cancer. Nippon Jibiinkoka Gakkai Kaiho 1998, 101:259-265.
32. Soussi T., Legros Y., Lubin R., Ory K., Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int. J. Cancer 1994, 1:1-9.
33. Todd R.C., Lippard S.J. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009, 4:280-291.
34. Tweddle D.A., Archie J., Malcolm N.B., et al. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res. 2001, 61:8-13.
35. Zhang Z.L., Liu Z.S., Sun Q. Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J. Gastroenterol. 2005, 2:216-220.
36. Zhou H., Fujigaki Y., Kato A., Miyaji T., Yasuda H., Tsuji T., Yamamoto T., Yonemura K., Hishida A. Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in rats. Am. J. Physiol. Renal Physiol. 2006, 291:225-235.